SyneuRx was founded in 2013 and is currently developing revolutionary new drugs. In the field of central nervous system, we prioritize schizophrenia, severe depression, and dementia. We have repeatedly proven in clinical studies that the effects are better than standard treatment and negligible side effects, it became the first company in the world to receive the breakthrough treatment designation from the US FDA for schizophrenia. Regarding COVID-19, SyneuRx’s strategy is to target patients with mild symptoms and develop oral dosage forms and inhaled dosage forms, to prevent and control the epidemic together with vaccines. SyneuRx's strength lies in combining innovation from the United States with Asia's abundant resources and production capacity. The team has strong R&D capabilities and rich clinical experience.